title: Histopathological response of transitional cell carcinoma to arsenic trioxide during the treatment of concurrently diagnosed acute promyelocytic leukaemia.
authors.forename: R
authors.initials: R
authors.lastname: Krishna
authors.forename: Y
authors.initials: Y
authors.lastname: Sorour
authors.forename: J R
authors.initials: JR
authors.lastname: Goepel
authors.forename: P
authors.initials: P
authors.lastname: Kirkbride
authors.forename: D J
authors.initials: DJ
authors.lastname: Smith
authors.forename: Y
authors.initials: Y
authors.lastname: Ezaydi
authors.forename: C D
authors.initials: CD
authors.lastname: Dalley
authors.forename: J A
authors.initials: JA
authors.lastname: Snowden
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology*; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000473:pathology*; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000473:pathology*; D010087:Oxides / Q000008:administration & dosage*; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D001152:Arsenicals; D010087:Oxides; D014212:Tretinoin; D000077237:Arsenic Trioxide